Yahoo Search Busca da Web

Entrar

Resultado da Busca

  1. Vídeos

    Ver tudo

  2. www.forbes.com › profile › mark-cubanMark Cuban - Forbes

    Há 3 dias · Today he owns a minority stake in the NBA's Dallas Mavericks and is cofounder of Cost Plus Drugs, which he launched in January 2022 with the aim of lowering prescription drug prices.

    • Owner

  3. www.bloomberg.com › billionaires › profilesBloomberg Billionaires Index - Mark Cuban

    Há 2 dias · Cuban sold a majority stake in the Mavericks for about $3.5 billion in November 2023. He confirmed in December 2023 that he retained a 27% stake in the Dallas-based team following the sale.

  4. www.forbes.com › profile › todd-wagnerTodd Wagner - Forbes

    Há 1 dia · Todd Wagner. With business partner Mark Cuban, Todd Wagner joined the billionaire ranks after selling video portal Broadcast.com to Yahoo in 1999. The $5.7 billion sale didn't just benefit Wagner...

  5. www.wfaa.com › article › sportsDallas Mavericks' deal for Klay Thompson was the NBA's first ...

    Há 1 dia · DALLAS — The Mavericks officially announced Saturday the deal that brought four-time NBA champion and five-time All-Star Klay Thompson to Dallas. The move was blockbuster in more ways than one ...

  6. www.dallasnews.com › sports › mavericksMavericks’ move for Klay Thompson officially part of first ...

    Há 1 dia · The Dallas Mavericks announced Saturday night that they acquired Thompson and a future second-round pick as part of a six-team sign-and-trade. The move goes down as the first six-team trade in NBA ...

  7. www.nytimes.com › athletic › 5613541/2024/07Why Klay Thompson chose Mavericks over Lakers and put the ...

    Há 5 dias · Thompson had bristled at the way Warriors owner Joe Lacob kept his distance from him all season, choosing not to ease his concerns about whether he was still a part of their plans.

  8. www.newsweek.com › mark-cuban-confronts-donaldMark Cuban Confronts Donald Trump Ally Mike Pompeo

    Há 3 dias · The billionaire owner of the Dallas Mavericks has been vocally critical of PBMs, which he argues play a significant role in inflating drug prices and distorting the pharmaceutical market.